激素治疗与女性中枢神经系统肿瘤风险:系统综述与荟萃分析
结果显示激素治疗与中枢神经系统肿瘤总体风险升高相关(OR=1.69;95%CI 1.28–2.23;p<0.001;I²=98.5%),主要源于脑膜瘤风险增加(OR=2.10;95%CI 1.52–2.91;I²=98.6%),而胶质瘤风险未见一致关联(OR=0.90;95%CI 0.64–1.27;I²=84.9%)。
要点
- 激素治疗与女性中枢神经系统肿瘤总体风险升高相关,主要由脑膜瘤驱动。
- 脑膜瘤风险显著增加(OR=2.10;95%CI 1.52–2.91)。
- 胶质瘤风险未见一致关联(OR=0.90;95%CI 0.64–1.27)。
核心结论
- 外源性激素治疗与女性中枢神经系统肿瘤风险升高相关,主要由脑膜瘤风险驱动,胶质瘤未见一致关联。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、Scopus和Web of Science数据库,纳入报告激素治疗与中枢神经系统肿瘤风险关联的研究。
- 统计分析使用R(版本4.4.2),显著性水平p<0.05。
主要发现
- 激素治疗与中枢神经系统肿瘤总体风险显著相关(OR=1.69;95%CI 1.28–2.23;p<0.001;I²=98.5%)。
- 亚组分析显示脑膜瘤风险增加(OR=2.10;95%CI 1.52–2.91;I²=98.6%)。
- 胶质瘤风险未见显著关联(OR=0.90;95%CI 0.64–1.27;I²=84.9%)。
- 以HR表达的中枢神经系统肿瘤总体风险为HR=1.18(95%CI 0.97–1.45;p=0.097;I²=71.0%),呈不显著趋势。
- 脑膜瘤HR=1.59(95%CI 1.09–2.32;I²=72.8%),胶质瘤HR=0.99(95%CI 0.86–1.16;I²=36%)。
关键数值与推荐
- 中枢神经系统肿瘤总体风险:OR=1.69(95%CI 1.28–2.23;p<0.001;I²=98.5%)。
- 脑膜瘤风险:OR=2.10(95%CI 1.52–2.91;I²=98.6%);HR=1.59(95%CI 1.09–2.32;I²=72.8%)。
- 胶质瘤风险:OR=0.90(95%CI 0.64–1.27;I²=84.9%);HR=0.99(95%CI 0.86–1.16;I²=36%)。
- 中枢神经系统肿瘤总体HR=1.18(95%CI 0.97–1.45;p=0.097;I²=71.0%)。
临床怎么用
- 临床评估女性激素治疗时,需关注中枢神经系统肿瘤风险,尤其是脑膜瘤风险升高。
- 对长期使用激素治疗的患者,应结合脑膜瘤风险进行个体化获益-风险讨论。
- 胶质瘤风险未见一致升高,不应以此作为限制激素治疗的依据。
局限性
- 纳入研究间异质性高(如总体OR的I²=98.5%)。
- 基于观察性研究的荟萃分析,可能存在混杂偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hormone therapy is widely used for contraception, disease treatment, and as hormone replacement therapy in women. Many studies have attempted to establish the relationship between the use of exogenous hormones and the development of CNS tumors; however, the results remain inconclusive. OBJECTIVES: The objective of this meta-analysis is to evaluate the association between hormone therapy use and the risk of developing central nervous system (CNS) tumors, particularly meningioma and glioma. METHODS: PubMed, Scopus, and Web of Science databases were searched for studies reporting the association between hormone therapy use and CNS tumor risk. The outcomes analyzed were overall risk for CNS tumors, meningioma, and glioma, described as odds ratios (ORs) and hazard ratios (HRs). Statistical analyses were performed using R (version 4.4.2), with a significance level of p < 0.05. RESULTS: The analysis of the 19 studies involving 2.398.681 patients demonstrated a significant association between hormone therapy use and the overall risk of CNS tumors (OR = 1.69; 95% CI, 1.28–2.23; p < 0.001; I² = 98.5%). Subgroup analysis revealed an increased risk for the development of meningioma (OR = 2.10; 95% CI, 1.52–2.91; I² = 98.6%), whereas for gliomas the exposure may not be associated with an increased risk (OR = 0.90; 95% CI, 0.64–1.27; I² = 84.9%). The overall risk of CNS tumors was also expressed using hazard ratios (HR = 1.18; 95% CI, 0.97–1.45; p = 0.097; I² = 71.0%), showing an insignificant trend favoring non-use of hormone therapy, with an increased risk observed for meningioma (HR = 1.59; 95% CI, 1.09–2.32; I² = 72.8%), while based on the analyzed data, hormone therapy use may not appear to increase the risk of glioma development (HR = 0.99; 95% CI, 0.86–1.16; I² = 36%). CONCLUSION: This meta-analysis suggests that exogenous hormonal therapy is associated with an increased risk of central nervous system tumors in women, driven predominantly by meningioma risk. No consistent association was observed for glioma.
引用
- Falcao V, Rego LHRM, Rodrigues PB, et al. Hormone therapy and the risk of central nervous system tumors in women: a systematic review and meta-analysis. J Neurooncol. 2026. PMID: 41721900. doi:10.1007/s11060-026-05462-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。